🔗 Share this article

While the United States continues making sweeping revisions to its immunization schedules, one figure appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on COVID-19 shots throughout the pandemic and has zeroed in on alleged fatalities after COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Schedule

Agency leaders planned to reveal radical changes to the childhood immunization program in December, bringing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of step with many the world with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was recently named acting director of the FDA’s CDER, the fifth person to head the division this calendar year.

A Shift at the FDA

The acting appointment may indicate a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting certain childhood vaccine recommendations in the US to become more in line with the Danish model, a nation with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccines – traditionally the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Background

The appointee has little discernible background in pharmaceutical research, oversight or leadership, which has been standard for former directors of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a sizeable institution. She lacks background in drug approvals.”

Previous directors of CBER would “grasp regulatory frameworks and the science of medication creation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who led CBER have had.”

The drug center has an immense workload at the agency, she pointed out.

“Many people just zeroes in on the new drug program, but the generic drug division clears numerous generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and each of these need to be looked after,” Dr. Woodcock noted. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a significant management component to the job, which supervises over 5,000 personnel. “It is a enormous leadership role, if you do it right,” she said.

Response and Disputed Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a press secretary stated that the “concerns rely on inaccurate premises”.

“This background aligns with the duties of her position,” the representative said, pointing to the period Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial expedited review system, a controversial one-day therapy clearance system that reportedly concerned her former heads. “How are these therapies being chosen for this voucher program? Who takes the calls?” Howard asked. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the FDA seems to be moving towards laxer rules of all drugs, aside from immunizations.”

Established History on Vaccines

With immunizations, Høeg has a clearer, if concerning, history, some experts said. She released a study using non-validated crowd-sourced reports to determine the frequency of myocarditis following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the incoming federal leadership encompassed revising rules for recently developed shots and ending “non-essential” vaccines, she stated after the election on a audio program. At the agency, Høeg has allegedly floated the idea of excluding adolescent males from obtaining Covid vaccines.

“She’s an thorough true believer who starts off with her conclusions and works backwards to retrofit the science in a extremely disingenuous, untruthful manner,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|